Kazia Therapeutics is pleased to share the latest Edison research report, which provides an updated view on Kazia’s clinical trial programme in the COVID-19 environment.
Edison says that the clinical trial schedule for both Cantrixil and lead candidate, paxalisib, remains on course. It says new data for Cantrixil “might be released by mid-2020”, while for paxalisib, the “potentially pivotal” GBM AGILE study “is on track for a H220 start.”
GBM AGILE is an international, academic-led, multi-drug adaptive phase II/III study in glioblastoma which will serve as the path-to-market for paxalisib.
“In the current viral pandemic, it is worth recalling that brain cancers will arise during and after the epidemic. The core business case for Kazia remains strong as it is developing the only brain penetrating PI3K inhibitor agent in trials to treat glioblastoma,” the report says.
Kazia plans to release data from both the paxalisib and Cantrixil trials in April.
Read the full report here.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Their lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial in 2018. Interim data was reported in November 2019, and further data
is expected in 1H 2020. GDC-0084 was granted orphan designation for glioblastoma by the US FDA in February 2018.